NCT02604511 · REGISTRY CONDITION SEARCH

Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2022-12-07

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Major Response Rate

→

outcome · POSTED

Best Overall Response Rate

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Time to Response

→

outcome · POSTED

Progression Free Survival

→

outcome · POSTED

Overall Survival

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Kyle et al, 2003). * Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of ≥ 2 times the upper limit of normal is required. * Age ≥ 18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (see Appendix A.). * Participants must have normal organ and marrow function as defined below: * Absolute neutrophil count ≥ 1,000/μL * Platelets ≥ 50,000/μL * Hemoglobin ≥ 8 g/dL * Total bilirubin ≤ 2.0. mg/dL or \< 2.5 mg/dL if attributable to hepatic infiltration by neoplastic disease or Gilbert's syndrome. * Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or SGPT) ≤ 2.5 X institutional upper limit of normal * Estimated Creatinine Clearance ≥30ml/min * Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin. * Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed. * Able to adhere to the study visit schedule and other protocol requirements. * Ability to understand and the willingness to sign a written informed consent document. * Both men and women of all races and ethnic groups are eligible for this trial. Exclusion Criteria: * Prior systemic therapy for WM * Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form. * Concurrent use of any other anti-cancer treatments or any other investigational agents. * Concomitant use of warfarin or other Vitamin K antagonists. * Concomitant treatment with strong CYP3A4/5 inhibitor. * Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. * Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could interfere with the absorption or metabolism of ibrutinib. * Known Central nervous system (CNS) lymphoma. * Concomitant use of medication known to cause QT prolongation. * Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within 6 months of screening. * Malabsorption, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction. * Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded. * Lactating or pregnant women. * Inability to swallow capsules. * History of non-compliance to medical regimens. * Unwilling or unable to comply with the protocol. * Major surgery within 4 weeks of first dose of study drug. * No active infections requiring systemic therapy. * Known bleeding disorders with the exception of acquired Von Willebrand Disorder suspected on the basis of WM. * History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.
intervention Names
Drug: Ibrutinib
label
Ibrutinib
type
EXPERIMENTAL

interventions

arm Group Labels
Ibrutinib
name
Ibrutinib
other Names
Imbruvica
PCI-32765
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 31
type: ACTUAL

Registered outcome plans (not posted results)

other Outcomes

description
The amount of time between starting treatment and attaining at least a minor response to therapy
measure
Time to Response
time Frame
4 years
description
The number of participants who have not experienced disease progression 6 years after therapy initiation
measure
Progression Free Survival
time Frame
6 years
description
The number of participants who are still living 6 years after initiation of ibrutinib
measure
Overall Survival
time Frame
6 years

primary Outcomes

description
To asses the percentage of participants with a Partial Response (PR) (50% reduction or more in serum IgM) or better.
measure
Major Response Rate
time Frame
4 years
description
To asses the percentage of participants with an Minor Response (MR) (25% reduction or more in serum IgM) or better.
measure
Best Overall Response Rate
time Frame
4 years

secondary Outcomes

description
The amount of time between attainment of at least a minor response and disease progression.
measure
Duration of Response
time Frame
6 years

Full study description

brief Summary: This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).
detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and Drug Administration) has approved ibrutinib as a form of treatment for the patient specific disease. Ibrutinib has been under investigation in research studies in participants with recurrent B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia, and WM. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated. The prior studies suggest that ibrutinib may be a useful treatment strategy for untreated WM patients. This study will test the safety and efficacy of ibrutinib as an option for untreated WM patients. The study will also conduct genomic sequencing of malignant WM cells before the start of treatment, and 6, 12, 24, 36 and 48 months afterwards. Genomic sequencing is the analysis of the entire DNA structure from tumor and normal cells. The purpose of this sequencing is to study which genetic changes effect how ibrutinib works. The results of these studies could also help in better understanding the course of WM disease, and be applicable to the development of other effective drug treatments.

Source references

references

citation
Sun H, Sklavenitis-Pistofidis R, Liu S, Liu X, Tsakmaklis N, Hatcher JM, Guerrera ML, Kofides A, Ramirez-Gamero A, Peachey AL, Li S, Keskin DB, Chea V, Kim N, Lyu H, Lu W, Livak KJ, Meid K, Guijosa A, Flynn CA, Pizzarella D, Patterson CJ, Hao M, Yi S, Yuan W, Branagan AR, Wu CJ, Ghobrial IM, Qiu L, Sarosiek SR, Castillo JJ, Hunter ZR, Treon SP. Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstrom macroglobulinemia. Blood. 2026 May 14;147(20):2298-2314. doi: 10.1182/blood.2025032268.
pmid
41671559
type
DERIVED
citation
Guijosa A, Ramirez-Gamero A, Sarosiek S, Branagan AR, von Keudell G, Treon SP, Castillo JJ. Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23;9(18):4705-4715. doi: 10.1182/bloodadvances.2025016536.
pmid
40674744
type
DERIVED
citation
Castillo JJ, Meid K, Gustine JN, Leventoff C, White T, Flynn CA, Sarosiek S, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Branagan AR, O'Donnell E, Raje N, Yee AJ, Patterson CJ, Hunter ZR, Treon SP. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia. 2022 Feb;36(2):532-539. doi: 10.1038/s41375-021-01417-9. Epub 2021 Sep 16.
pmid
34531537
type
DERIVED
citation
Treon SP, Gustine J, Meid K, Yang G, Xu L, Liu X, Demos M, Kofides A, Tsakmaklis N, Chen JG, Munshi M, Chan G, Dubeau T, Raje N, Yee A, O'Donnell E, Hunter ZR, Castillo JJ. Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755-2761. doi: 10.1200/JCO.2018.78.6426. Epub 2018 Jul 25.
pmid
30044692
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-bca851d31c11c171d57a
requested nct id
NCT02604511
primary nct id
NCT02604511
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
d4982ff7b340eaadb281ec91abf194d854018bcfd321114e04f0c22ef1446382
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-bca851d31c11c171d57a
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT02604511
occurrences
context exact
NCT02604511
end
11
exact text
NCT02604511
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/143/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
298e5b8379aa004e98fb4541b7c8a01e53fe4b75d3f898d4259889d4c28ec408
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice